German
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021
Organization streamlined with a focus on cost savings and progressing vamorolone
Preliminary unaudited result for 2020: net sales CHF 15.0 million; net loss CHF 71.2 million; cash on hand as of December 31, 2020, CHF 12.4 million
Upsized financing from fund managed by Highbridge Capital Management, LLC (an existing investor in the Company), to satisfy liquidity needs through the next value-inflection point
Further strengthening of Santhera’s capital structure through a proposed convertible bond restructuring supported by its largest convertible bondholder representing approx. 32% of total bonds outstanding
Santhera Pharmaceuticals Holding AG: Santhera Announces Corporate Update and Proposal to Strengthen Capital Structure
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021
Organization streamlined with a focus on cost savings and progressing vamorolone
Preliminary unaudited result for 2020: net sales CHF 15.0 million; net loss CHF 71.2 million; cash on hand as of December 31, 2020, CHF 12.4 million
Upsized financing from fund managed by Highbridge Capital Management, LLC (an existing investor in the Company), to satisfy liquidity needs through the next value-inflection point
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
Aachen, Germany, 12 February
2021 / News Aktuell – Grünenthal has announced the successful extension of its existing €535 million term loan bank facilities. This amendment was conducted in the broader context of the company’s acquisition of the European rights (excluding Spain and the UK) to the lipid-lowering medication CRESTOR™ completed in February 2021. The term loan maturities are now aligned with Grünenthal’s Revolving Credit Facility maturity, which further extends its debt maturity profile. More than 60 percent of Grünenthal’s debt facilities now mature in 2024 or later.
“By extending the maturity of our financing, we have gained additional flexibility to further fund our growth strategy,” says Fabian Raschke, Chief Financial Officer of Grünenthal. „W
Grünenthal closes deal with AstraZeneca for European rights to CRESTOR (rosuvastatin)
AACHEN, Germany, Feb. 10, 2021 /PRNewswire/ Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR (excluding Spain and the UK) for a total consideration of up to US$ 350 million. Cardiovascular diseases are among the most burdensome diseases in Europe
1, said Gabriel Baertschi, CEO Grünenthal. With CRESTOR, we are proud to provide a meaningful therapy option to those patients. The completion of this acquisition is an important milestone for Grünenthal.
Under the terms of this agreement, Grünenthal has acquired the exclusive rights to market CRESTOR and its second brands in more than 30 European markets. Grünenthal will also take over bulk production and packaging for the defined markets by 2025. CRESTOR continues to generate significant revenues, total CRESTOR 2019 sales in the countries where rights were acquired were US$ 136 milli
Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™ (rosuvastatin)
News provided by
Share this article
Share this article
AACHEN, Germany, Feb. 10, 2021 /PRNewswire/ Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR™ (excluding Spain and the UK) for a total consideration of up to US$ 350 million. Cardiovascular diseases are among the most burdensome diseases in Europe
1, said Gabriel Baertschi, CEO Grünenthal. With CRESTOR™, we are proud to provide a meaningful therapy option to those patients. The completion of this acquisition is an important milestone for Grünenthal.
Under the terms of this agreement, Grünenthal has acquired the exclusive rights to market CRESTOR™ and its second brands in more than 30 European markets. Grünenthal will also take over bulk production and packaging for the defined markets by 2025. CRESTOR™ continues to generate significant revenues, total CRESTOR